PT - JOURNAL ARTICLE AU - Jack Bowden AU - Luke C. Pilling AU - Deniz Türkmen AU - Chia-Ling Kuo AU - David Melzer TI - The Triangulation WIthin A STudy (TWIST) framework for causal inference within Pharmacogenetic research AID - 10.1101/2021.05.04.21256612 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.04.21256612 4099 - http://medrxiv.org/content/early/2021/07/23/2021.05.04.21256612.short 4100 - http://medrxiv.org/content/early/2021/07/23/2021.05.04.21256612.full AB - In this paper we review the methodological underpinnings of the general pharmacogenetic approach for uncovering genetically-driven treatment effect heterogeneity. This typically utilises only individuals who are treated and relies on fairly strong baseline assumptions to estimate what we term the ‘genetically moderated treatment effect’ (GMTE). When these assumptions are seriously violated, we show that a robust but less efficient estimate of the GMTE that incorporates information on the population of untreated individuals can instead be used. In cases of partial violation, we clarify when Mendelian randomization and a modified confounder adjustment method can also yield consistent estimates for the GMTE. A decision framework is then described to decide when a particular estimation strategy is most appropriate and how specific estimators can be combined to further improve efficiency. Triangulation of evidence from different data sources, each with their inherent biases and limitations, is becoming a well established principle for strengthening causal analysis. We call our framework ‘Triangulation WIthin a STudy’ (TWIST)’ in order to emphasise that an analysis in this spirit is also possible within a single data set, using causal estimates that are approximately uncorrelated, but reliant on different sets of assumptions. We illustrate these approaches by re-analysing primary-care-linked UK Biobank data relating to CYP2C19 genetic variants, Clopidogrel use and stroke risk, and data relating to APOE genetic variants, statin use and Coronary Artery Disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJB was funded by an Expanding Excellence in England (E3) research grant awarded to the University of Exeter CLK, LCP, and DM are supported by the R21 grant, R21AG060018, funded by the National Institute on Aging, National Institute of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:no ethical approval neededAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this paper comes from UK Biobank, which is publicly available to all bona fide researchers worldwide following a formal application